



US011413308B2

(12) **United States Patent**
Braithwaite et al.

(10) **Patent No.:** US 11,413,308 B2
(45) **Date of Patent:** *Aug. 16, 2022

(54) **DOSING REGIMEN FOR TREATMENT OF COGNITIVE AND MOTOR IMPAIRMENTS WITH BLOOD PLASMA AND BLOOD PLASMA PRODUCTS**

(71) Applicant: **Alkahest, Inc.**, San Carlos, CA (US)

(72) Inventors: **Steven P. Braithwaite**, Redwood City, CA (US); **Eva Czirr**, Foster City, CA (US); **Ian Gallagher**, Half Moon Bay, CA (US); **Nina Huber**, Redwood City, CA (US); **S. Sakura Minami**, San Francisco, CA (US)

(73) Assignee: **Alkahest, Inc.**, San Carlos, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: 17/097,702

(22) Filed: Nov. 13, 2020

(65) **Prior Publication Data**

US 2021/0060063 A1 Mar. 4, 2021

Related U.S. Application Data

(63) Continuation of application No. 16/432,114, filed on Jun. 5, 2019, now Pat. No. 10,874,692, which is a continuation of application No. 15/961,618, filed on Apr. 24, 2018, now Pat. No. 10,357,513.

(60) Provisional application No. 62/490,519, filed on Apr. 26, 2017, provisional application No. 62/584,571, filed on Nov. 10, 2017, provisional application No. 62/623,468, filed on Jan. 29, 2018, provisional application No. 62/641,194, filed on Mar. 9, 2018.

(51) **Int. Cl.**

A61K 35/16 (2015.01)
A61P 25/28 (2006.01)
A61K 9/00 (2006.01)
A61K 38/17 (2006.01)
A61K 38/01 (2006.01)

(52) **U.S. Cl.**

CPC A61K 35/16 (2013.01); A61K 9/0026 (2013.01); A61K 38/017 (2013.01); A61K 38/1722 (2013.01); A61P 25/28 (2018.01)

(58) **Field of Classification Search**

CPC A61K 38/38; A61K 35/16; A61P 25/28;
A61P 25/00

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,900,720 A 2/1990 Kotitschke
5,916,202 A 6/1999 Haswell
6,632,174 B1 10/2003 Breznitz

6,946,546 B2	9/2005	Vaughan et al.
7,785,601 B2	8/2010	Schaebitz et al.
7,851,446 B2	12/2010	Roura
2002/0143283 A1	10/2002	Braverman et al.
2002/0151064 A1	10/2002	Rothenberg et al.
2003/0157687 A1	8/2003	Greene et al.
2004/0120937 A1	6/2004	Wilson
2004/0127445 A1	7/2004	Liew et al.
2004/0141946 A1	7/2004	Schaebitz et al.
2004/0254152 A1	12/2004	Monje et al.
2005/0221348 A1	10/2005	Ray et al.
2006/0094064 A1	5/2006	Ray et al.
2006/0198851 A1	9/2006	Basi et al.
2006/0263759 A1	11/2006	Alves-Filho et al.
2007/0037200 A1	2/2007	Ray et al.
2007/0155725 A1	7/2007	Li et al.
2007/0190055 A1	8/2007	Ambati
2008/0026485 A1	1/2008	Hueber et al.
2008/0057590 A1	3/2008	Urdea et al.
2009/0111740 A1*	4/2009	Grifols Roura A61K 38/38 514/1.1
2009/0143394 A1	6/2009	Wyss-Coray et al.
2009/0181008 A1	7/2009	Ray et al.
2009/0239241 A1	9/2009	Ray et al.
2010/0080850 A1	4/2010	Hubbel et al.
2010/0124756 A1	5/2010	Ray et al.
2010/0258496 A1	10/2010	Hidaka et al.
2010/0310609 A1	12/2010	Watson et al.
2010/0324079 A1	12/2010	Ohyagi

(Continued)

FOREIGN PATENT DOCUMENTS

EP	19930184040 B1	4/1993
EP	2111868 B1	8/2013

(Continued)

OTHER PUBLICATIONS

Castellano et al, Human umbilical cord plasma proteins revitalize hippocampal function in aged mice. Nature, (Apr. 27, 2017) vol. 544, No. 7651, pp. 488-492. Electronic Publication Date: Apr. 19, 2017 (Year: 2017).*

Baker et al, Aerobic exercise reduces phosphorylated tau protein in cerebrospinal fluid in older adults with mild cognitive impairment. Alzheimer's and Dementia, (Jul. 2015) vol. 11, No. 7, Supp. Suppl. 1, pp. P324 (Year: 2015).*

Adair et al., "Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease." Stroke Jun. 2004;35(6):e159-62.

Adkins et al., "Toward a Human Blood Serum Proteome", (2002) Molecular & Cellular Proteomics 1: 947-955.

(Continued)

Primary Examiner — Qiuwen Mi

(74) **Attorney, Agent, or Firm** — Mandar A. Joshi; Bret E. Field; Bozicevic, Field & Francis LLP

(57)

ABSTRACT

Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating and/or preventing aging-related conditions such as cognitive disorders. The methods relate to a regimen of pulsed dosing of blood plasma or blood plasma fractions.

(56)

References Cited**U.S. PATENT DOCUMENTS**

2011/0117100 A1	5/2011	Britschgi et al.
2011/0202284 A1	8/2011	McReynolds et al.
2011/0212854 A1	9/2011	Ray et al.
2011/0243947 A1	10/2011	Doody et al.
2012/0095000 A1	4/2012	Wyss-Coray et al.
2012/0258075 A1	10/2012	Wyss-Coray et al.
2013/0040844 A1	2/2013	Wyss-Coray et al.
2013/0302322 A1	11/2013	Wong et al.
2014/0011689 A1	1/2014	Sandip et al.
2014/0121438 A1	6/2014	Quirk
2014/0255424 A1	9/2014	Wyss-Coray et al.
2015/0079045 A1	3/2015	Kong
2015/0157664 A1	6/2015	Wyss-Coray et al.
2016/0143996 A1	5/2016	Wyss-Coray et al.
2016/0208011 A1	7/2016	Wyss-Coray et al.
2017/0081415 A1	3/2017	Wong et al.
2017/0232118 A1	8/2017	Wyss-Coray et al.
2018/0110839 A1	4/2018	Bell et al.

FOREIGN PATENT DOCUMENTS

JP	2016-539992 A	12/2016
RU	2428997 C1	9/2011
RU	2470677 C1	12/2012
UA	35656 C2	4/2001
WO	WO2005052592 A2	6/2005
WO	WO2005106492 A2	11/2005
WO	WO2006133423 A1	12/2006
WO	WO2007059135 A2	5/2007
WO	WO2009023814 A2	2/2009
WO	WO2009055729 A1	4/2009
WO	WO2009155069 A1	12/2009
WO	WO2011094535 A2	8/2011
WO	WO2013142135 A1	9/2013
WO	WO2013184646 A2	12/2013
WO	WO2015088915 A1	6/2015
WO	WO2016187217 A2	11/2016
WO	WO2016205004 A2	12/2016
WO	WO2017120461 A1	7/2017
WO	WO2018200560 A1	11/2018

OTHER PUBLICATIONS

- Anderson et al., "The Human Plasma Proteome", (2002) Molecular & Cellular Proteomics 1: 845-867.
- Anderson et al., "High resolution two-dimensional electrophoresis of human plasma proteins", (1977) Proc. Natl. Acad. Sci. vol. 74, No. 12, pp. 5421-5425.
- Baba et al., "Timp-3 deficiency impairs cognitive function in mice." Lab Invest. Dec. 2009;89(12):1340-7.
- Berezovskaya et al., "Colony stimulating factor-1 potentiates neuronal survival in cerebral cortex ischemic lesion." Acta Neuropathol. Nov. 1996;92(5):479-86.
- Boissonneault et al., "Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease." Brain. Apr. 2009;132(Pt 4):1078-92.
- Bouchard et al., "Aging and brain rejuvenation as systemic events," J. Neurochem. Jan. 2015; 132(1):5-19.
- Britschgi et al., "Blood protein signature for the early diagnosis of Alzheimer disease." Arch Neurol. Feb. 2009;66(2):161-5.
- Cheung et al., "Serum β -2 microglobulin predicts mortality in people with diabetes." Eur J Endocrinol. May 17, 2013;169(1):1-7.
- Fedoroff et al., "Role of colony stimulating factor-1 in brain damage caused by ischemia." Neurosci Biobehav Rev. Mar. 1997;21(2):187-91.
- Gowing et al., "Macrophage colony stimulating factor (M-CSF) exacerbates ALS disease in a mouse model through altered responses of microglia expressing mutant superoxide dismutase." Exp Neurol. Dec. 2009;220(2):267-75.
- Jha, "Young blood can reverse some effects of ageing, study finds," The Guardian, Oct. 17, 2012, 4 pages.
- Kwak et al., "Aging, exercise, and extracellular matrix in the heart." J Exerc Rehabil. Jun. 30, 2013;9(3):338-47.
- Lin et al., "Discovery of a cytokine and its receptor by functional screening of the extracellular proteome." Science. May 9, 2008;320(5877):807-11.
- Luo et al., "Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival." J. Exp. Med. (2013) 210(1):157-172.
- Lysaght et al., "Beta-2 microglobulin removal during continuous ambulatory peritoneal dialysis (CAPD)." Perit Dial Int. 1989;9(1):29-35.
- Malkki, "Ageing: Could young blood combat age-related cognitive decline?" Nat. Rev. Neurol. Jun. 2014;10(6):307.
- Manzo et al., "Role of chemokines and chemokine receptors in regulating specific leukocyte trafficking in the immune/inflammatory response." Clin Exp Rheumatol. Jul.-Aug. 2003;21(4):501-8.
- McLaurin et al., "Microglial pilgrimage to the brain." Nat Med. Dec. 2010;16(12):1380-1.
- Middeldorp et al., "A young systemic environment reverses degeneration in a mouse model of Alzheimer's disease," Neuroscience 2012, Presentation Abstract, Oct. 16, 2012, 2 pages.
- Mitrasinovic et al., "Microglia overexpressing the macrophage colony-stimulating factor receptor are neuroprotective in a microglial hippocampal organotypic coculture system." J Neurosci. Apr. 27, 2005;25(17):4442-51.
- Mizuno et al., "Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid- β neurotoxicity." Am J Pathol. Oct. 2011;179(4):2016-27.
- Palop et al., "A network dysfunction perspective on neurodegenerative diseases." Nature. Oct. 19, 2006;443(7113):768-73.
- Prakasam et al., "Amyloid and neurodegeneration: Alzheimer's disease and retinal degeneration." Chapter 7, Handbook of Neurochemistry and Molecular Neurobiology, Lajtha ed., 2009, 131-163. (Year: 2009).
- Ron-Harel et al., "Age-Dependent Spatial Memory Loss Can Be Partially Restored by Immune Activation," Rejuvenation Resarch (2008), 11(5):903-13.
- Royer et al., "A novel antagonist of prostaglandin 02 blocks the locomotion of eosinophils and basophils." Eur J Clin Inves. Sep. 2008;38(9):663-71.
- Schwartz et al., "How Do Immune Cells Support and Shape the Brain in Health, Disease, and Aging?" The Journal of Neuroscience, Nov. 6, 2013, 33(45):17587-96.
- Sellebjerg et al., "Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation." Eur J Neurol. Dec. 2009;16(12):1291-8.
- Shin et al., "Association of eotaxin gene family with asthma and serum total IgE." Hum Mol Genet. Jun. 1, 2003;12(11):1279-85.
- Skovronsky et al., "Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications." Annu Rev Pathol. 2006;1: 151-70.
- Smith et al., " β 2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis." Nat Med. Aug. 2015;21(8):932-7.
- Strobel et al., "Chicago: the vampire principle—young blood rejuvenates aging brain?" Alzheimer Research Forum (Nov. 2009), p. 1-3.
- Stubbs et al., "Indomethacin causes prostaglandin 0(2)-like and eotaxin-like selective responses in eosinophils and basophils." J Biol Chem. Jul. 19, 2002;277(29):26012-20.
- Teixeira et al., "Increased serum levels of CCL 11/eotaxin in schizophrenia," "Process in neuro-psychopharmacology & biological psychiatry," vol. 32, No. 3, pp. 710-714, 2008.
- Thomson et al., "Young blood for a keener mind," New Scientist (2012), 216(2887): 10.
- Villeda et al., "Changes in the systemic milieu modulate neurogenesis during aging." Abstract, 39th Annual Neuroscience Meeting, Chicago, IL, Society for Neuroscience, Oct. 2009, 1-2. (Year: 2009).